Sanofi begins three-year immunology R&D tie-up with StanfordSanofi has begun a three-year research collaboration with Stanford University School of Medicine, working on better understanding of Share XSanofi begins three-year immunology R&D tie-up with Stanfordhttps://pharmaphorum.com/news/sanofi-begins-three-year-immunology-rd-tie-up-with-stanford-university/
Rubius launches $200m IPO to fund red blood cell therapiesRubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel Share XRubius launches $200m IPO to fund red blood cell therapieshttps://pharmaphorum.com/news/rubius-launches-200m-ipo-for-red-blood-cell-therapies/
NIH abandons convalescent plasma trial in mild COVIDAnother trial of convalescent plasma in people with COVID-19 has missed the mark, this time in mild to Share XNIH abandons convalescent plasma trial in mild COVIDhttps://pharmaphorum.com/news/nih-abandons-convalescent-plasma-trial-in-mild-covid/
Data sets up ulcerative colitis expansion for BMS’ MS drug ZeposiaBristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – Share XData sets up ulcerative colitis expansion for BMS’ MS drug Zeposiahttps://pharmaphorum.com/news/data-sets-up-ulcerative-colitis-expansion-for-bms-ms-drug-zeposia/
IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialHopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results Share XIL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialhttps://pharmaphorum.com/news/il-6-hypothesis-looking-shaky-as-kevzara-fails-covid-19-trial/
Kadmon preps filing for GVHD drug belumosudil after phase 3 winNew York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus Share XKadmon preps filing for GVHD drug belumosudil after phase 3 winhttps://pharmaphorum.com/news/kadmon-preps-filing-for-gvhd-drug-belumosudil-after-phase-3-win/
Innovating in inflammation and immunologyFor World Inflammatory Bowel Disease day we spoke to Pfizer’s Matt Shaulis, president of international developed markets for Share XInnovating in inflammation and immunologyhttps://pharmaphorum.com/r-d/views-analysis-r-d/innovating-in-inflammation-and-immunology/
Blockbusters in waiting: drug launches to watch in 2020New drugs for breast cancer, lymphoma, multiple sclerosis and migraine are among new product launches this year that Share XBlockbusters in waiting: drug launches to watch in 2020https://pharmaphorum.com/news/blockbusters-in-waiting-drug-launches-to-watch-in-2020/
3 key trends shaping the immunology marketFrom an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an Share X3 key trends shaping the immunology markethttps://pharmaphorum.com/views-analysis-market-access/3-key-trends-shaping-the-immunology-market/
